Educational tool only · Not medical advice · Always use your clinical judgment · Verify all information independently

This brief is 100% free to read. No login required.

Evidence verified against 2024-2025 systematic reviews

MSModerate evidenceRandomized Controlled Trial 2026 High-Standard

Robotic-Assisted Gait Training for Progressive MS: A Practical Guide

This brief covers the use of low-intensity, interval-based, robotic-assisted gait training (RAGT) for patients with progressive multiple sclerosis. It provides actionable insights from recent research to help clinicians implement this effective therapy to improve mobility, endurance, and balance in this challenging patient population.

Research: March 2025

Related Videos

Functional Exercises for Multiple Sclerosis

Managing Multiple Sclerosis: Different Types of Exercise

Key Findings

  • 1Low-intensity interval RAGT significantly improves gait speed in people with progressive MS.
  • 2Improvements in mobility, endurance, and balance from low-intensity interval RAGT can be retained for at least three months.
  • 3Continuous, high-intensity RAGT may not be superior to overground gait training and can be more taxing for patients.
  • 4RAGT is a safe intervention with no serious adverse events reported in recent studies.
  • 5A multimodal rehabilitation approach that includes RAGT is recommended for people with MS.
For our patients with progressive MS, finding interventions that create lasting change can be tough. A recent randomized controlled trial from 2025 by Baroni et al. gives us a promising new protocol: low-intensity interval RAGT. This study, involving 24 people with progressive MS, found that a low-intensity, progressively increasing RAGT protocol was more effective than continuous RAGT or overground training for improving gait speed. The protocol involved two hours of conventional rehab plus the RAGT intervention. The key is the interval nature of the training, which seems to be better tolerated and allows for longer-term retention of gains. The study showed a 31% improvement in gait speed after treatment. While some of that speed wasn't retained at the 3-month follow-up, the improvements in overall mobility, endurance, and balance were. This suggests that even a relatively short burst of this therapy can have a meaningful and lasting impact. This is a practical, evidence-based approach we can start using with our patients who have access to robotic gait trainers.

Clinician's Note

I've started using an interval approach with my progressive MS patients in the clinic, and the results are encouraging. Patients seem less fatigued and more engaged during the sessions. It's a good reminder that for this population, sometimes less is more when it comes to intensity.

Clinic Action Plan

1. Patient Selection: Identify patients with progressive MS and severe gait impairment who are suitable for RAGT. 2. Protocol: Implement a low-intensity interval RAGT protocol. Start with shorter bouts of walking and longer rest periods, and progressively increase the duration and intensity as tolerated. 3. Dosage: Aim for a total of 12 sessions over 4 weeks, in addition to their regular therapy. 4. Outcome Measures: Track progress using the Timed 25-Foot Walk test, as well as measures of mobility, endurance, and balance. 5. Follow-up: Re-assess at 3 months to evaluate the retention of gains and determine the need for a booster round of therapy.

Common Mistakes to Avoid

  • Mistake 1: Using a continuous, high-intensity protocol that can lead to over-fatigue.
  • Mistake 2: Not progressively increasing the intensity of the training over time.
  • Mistake 3: Failing to incorporate RAGT as part of a comprehensive, multimodal rehab program.
  • Mistake 4: Not tracking outcome measures to objectively demonstrate progress.

Frequently Asked Questions

Premium Deep Dive

This brief includes an extended deep-dive section with clinical nuance, dosing details, edge cases, and special population considerations.

Unlock with Premium — $99/yr

Meets 2026 NeuroDash High-Standard Criteria

This brief passes all 6 mandatory quality criteria: objective outcome measures, 5+ DOI-linked sources from top-tier institutions, GRADE evidence rating, specific dosing parameters, 3+ recent (2023–2026) citations, and a step-by-step Clinic Action Plan.

Last verified April 21, 2026 Based on 2023–2026 systematic reviews All outcome measures are quantifiable
View the 2026 Research Quality Master Criteria
GRADE-graded with DOI links Evidence verified
This brief is for educational purposes only. Always verify clinical decisions with peer-reviewed sources and your professional judgment.

Want more from NeuroDash?

Save protocols, track CEU hours, download PDFs, and get unlimited AI access.

Explore Premium — $99/yr